This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koivunen, J. P. Articles by Jänne, P. A. Search for Related Content PubMed PubMed Citation Articles by Koivunen, J. P. Articles by Jänne, P. A.

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Authors' Affiliations: ¹ Lowe Center for Thoracic Oncology and Departments of ² Medical Oncology and ³ Cancer Biology, Dana-Farber Cancer Institute; Departments of ⁴ Pathology and ⁵ Medicine, Brigham and Women's Hospital and Harvard Medical School; ⁶ Massachusetts General Hospital Cancer Center; ⁷ Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; ⁸ Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts; ⁹ The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts; ¹⁰ Department of Thoracic Surgery, Samsung Medical Center; ¹¹ Sungkyunkwan University School of Medicine, Seoul, Korea; and ¹² Max-Planck Institute, Cologne, Germany

Requests for reprints: Pasi A. Jänne, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, D820A, 44 Binney Street, Boston, MA 02115. Phone: 617-632-6036; Fax: 617-582-7683; E-mail: pjanne{at}partners.org.

Purpose: The EML4-ALK fusion gene has been detected in 7% of Japanese non-small cell lung cancers (NSCLC). We determined the frequency of EML4-ALK in Caucasian NSCLC and in NSCLC cell lines. We also determined whether TAE684, a specific ALK kinase inhibitor, would inhibit the growth of EML4-ALK-containing cell lines in vitro and in vivo.

Experimental Design: We screened 305 primary NSCLC [both U.S. (n = 138) and Korean (n = 167) patients] and 83 NSCLC cell lines using reverse transcription-PCR and by exon array analyses. We evaluated the efficacy of TAE684 against NSCLC cell lines in vitro and in vivo.

Results: We detected four different variants, including two novel variants, of EML4-ALK using reverse transcription-PCR in 8 of 305 tumors (3%) and 3 of 83 (3.6%) NSCLC cell lines. All EML4-ALK-containing tumors and cell lines were adenocarcinomas. EML4-ALK was detected more frequently in NSCLC patients who were never or light (<10 pack-years) cigarette smokers compared with current/former smokers (6% versus 1%; P = 0.049). TAE684 inhibited the growth of one of three (H3122) EML4-ALK-containing cell lines in vitro and in vivo, inhibited Akt phosphorylation, and caused apoptosis. In another EML4-ALK cell line, DFCI032, TAE684 was ineffective due to coactivation of epidermal growth factor receptor and ERBB2. The combination of TAE684 and CL-387,785 (epidermal growth factor receptor/ERBB2 kinase inhibitor) inhibited growth and Akt phosphorylation and led to apoptosis in the DFCI032 cell line.

Conclusions: EML4-ALK is found in the minority of NSCLC. ALK kinase inhibitors alone or in combination may nevertheless be clinically effective treatments for NSCLC patients whose tumors contain EML4-ALK.

This article has been cited by other articles:

				F. J. Kaye Mutation-associated fusion cancer genes in solid tumors Mol. Cancer Ther., June 1, 2009; 8(6): 1399 - 1408. [Abstract] [Full Text] [PDF]

				K. Takeuchi, Y. L. Choi, Y. Togashi, M. Soda, S. Hatano, K. Inamura, S. Takada, T. Ueno, Y. Yamashita, Y. Satoh, et al. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer Clin. Cancer Res., May 1, 2009; 15(9): 3143 - 3149. [Abstract] [Full Text] [PDF]

				R. E. George and A. Thomas Look Therapeutic Implications of ALK Mutations in Neuroblastoma Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 113 - 115. [Full Text] [PDF]

				M. P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro, D. Conte, P. Gasparini, F. Perrone, P. Modena, U. Pastorino, et al. EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues Am. J. Pathol., February 1, 2009; 174(2): 661 - 670. [Abstract] [Full Text] [PDF]

				M. Soda, S. Takada, K. Takeuchi, Y. L. Choi, M. Enomoto, T. Ueno, H. Haruta, T. Hamada, Y. Yamashita, Y. Ishikawa, et al. A mouse model for EML4-ALK-positive lung cancer PNAS, December 16, 2008; 105(50): 19893 - 19897. [Abstract] [Full Text] [PDF]